Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125780762 | 12578076 | 2 | F | 20160801 | 20160721 | 20160809 | EXP | US-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023680 | GLENMARK | SAIFEE N H, RANJITKAR P, GREENE D N, BAIRD G S.. SPECTRAL WAVELENGTH AND PH: A MECHANISM FOR NAPROXEN METABOLITE POSITIVE INTERFERENCE IN TOTAL BILIRUBIN ASSAYS.. AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2015;143(1):A021 | 0.00 | Y | 0.00000 | 20160809 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125780762 | 12578076 | 1 | PS | NAPROXEN. | NAPROXEN | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125780762 | 12578076 | 1 | Suicide attempt |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125780762 | 12578076 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125780762 | 12578076 | Hyperbilirubinaemia | |
125780762 | 12578076 | Overdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |